Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]
News [3134]
Articles [127]
Editorials [3]
Conferences [119]
elearning [13]
Synergy of kinase inhibitors in imatinib-resistant CML
Synergy of kinase inhibitors in imatinib-resistant CML
Bortezomib licensed for subcutaneous administration
Bortezomib licensed for subcutaneous administration
ESMO 2012: Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
ESMO 2012: Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
Cancer death rates set to drop 17 per cent by 2030
Cancer death rates set to drop 17 per cent by 2030
Double assault on tough types of leukaemias
Double assault on tough types of leukaemias
Aprea announces positive data from a clinical Phase I/II study with APR-246 in patients with advanced cancers
Aprea announces positive data from a clinical Phase I/II study with APR-246 in patients with advanced cancers
Molecule shows effectiveness against drug-resistant myeloma
Molecule shows effectiveness against drug-resistant myeloma
Possible new therapy for the treatment of a common blood cancer
Possible new therapy for the treatment of a common blood cancer
Adding bavituximab to second-line chemotherapy doubles response rate
Adding bavituximab to second-line chemotherapy doubles response rate
Almost one in five young children with cancer suffers from a trauma disorder
Almost one in five young children with cancer suffers from a trauma disorder

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation